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Highlights
 A short-duration, pangenotypic cure for HCV infection may
help treat more patients.
 Glecaprevir plus pibrentasvir (G/P) therapy for 8 weeks had
an overall cure rate of 98%.
 The efficacy of 12-week G/P therapy (99%) was not signif-
icantly higher than that of 8-week G/P therapy (p = 0.2).
 Treatment responses were high irrespective of any baseline
patient or viral trait.
 G/P demonstrated a favourable safety profile regardless of
treatment duration.Massimo Puoti, Graham R. Foster, Stanley
Wang, ..., Sandra Lovell, Tami Pilot-Matias,
Federico J. Mensa
Correspondence
massimo.puoti@fastwebnet.it
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Lay summary
In this integrated analysis of nine clinical
trials, patients with chronic HCV geno-
type 1–6 infection without cirrhosis were
treated for either 8 or 12 weeks with the
direct-acting antiviral regimen glecapre-
vir/pibrentasvir (G/P). The cure rate was
98% and 99% following 8 and 12 weeks of
treatment, respectively; the difference in
rates was not significant (p = 0.2), nor was
there a significant difference in the cure
rates across the two treatment durations
on the basis of baseline patient or viral
characteristics. These results, along with a
favourable safety profile, indicate that G/P
is a highly efficacious and well-tolerated
pangenotypic eight-week therapy for
most patients with chronic HCV infection.Viral HepatitisJ. Hepatol. 2018, 69, 293–300
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Lay summary: In this integrated analysis of nine clinical trials,
patients with chronic HCV genotype 1–6 infection without cir-
rhosis were treated for either 8 or 12 weeks with the direct-
acting antiviral regimen glecaprevir/pibrentasvir (G/P). The cure
rate was 98% and 99% following 8 and 12 weeks of treatment,
respectively; the difference in rates was not signiﬁcant (p =
0.2), nor was there a signiﬁcant difference in the cure rates
across the two treatment durations on the basis of baseline
patient or viral characteristics. These results, along with a
favourable safety proﬁle, indicate that G/P is a highly efﬁcacious
and well-tolerated pangenotypic eight-week therapy for most
patients with chronic HCV infection.
 2018 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Background & Aims: Glecaprevir plus pibrentasvir (G/P) is a
pangenotypic, once-daily, ribavirin-free direct-acting antiviral
(DAA) treatment for hepatitis C virus (HCV) infection. In nine
phase II or III clinical trials, G/P therapy achieved rates of sus-
tained virologic response 12 weeks after treatment (SVR12) of
93–100% across all six major HCV genotypes (GTs). An inte-
grated efﬁcacy analysis of 8- and 12-week G/P therapy in
patients without cirrhosis with HCV GT 1–6 infection was
performed.
Methods: Data were pooled from nine phase II and III trials
including patients with chronic HCV GT 1–6 infection without
cirrhosis who received G/P (300 mg/120 mg) for either 8 or
12 weeks. Patients were treatment naïve or treatment experi-
enced with peginterferon, ribavirin, and/or sofosbuvir; all
patients infected with HCV GT 3 were treatment naïve. Efﬁcacy
was evaluated as the SVR12 rate.
Results: The analysis included 2,041 patients without cirrhosis.
In the intent-to-treat population, 943/965 patients (98%)
achieved SVR12 when treated for eight weeks, and
Introduction
Hepatitis C virus (HCV) infects an estimated 71–80 million
individuals worldwide, and is a leading cause of cirrhosis,
hepatocellular carcinoma, and liver-related deaths.1 The era of
direct-acting antiviral (DAA) agents for the treatment of HCV
infection has resulted in a rapid and steady decline in the
number of infected patients and an improvement in disease out-
comes. As more patients with chronic HCV infection are being
treated, it is projected that up to 75% of new patients will be
HCV treatment naïve and without cirrhosis.2
According to recent US and European guidelines, most
approved regimens for patients with HCV infection without cir-
rhosis have treatment durations of 12 weeks or more.3,4 Shorter
treatment durations have been associated with improved
adherence, which may beneﬁt difﬁcult-to-treat populations,
such as prisoners, psychiatric patients, and injection drug
users.5–8 Until recently, there were only two options for a
shorter, eight-week duration for patients with HCV genotype 11,060/1,076 patients (99%) achieved SVR12 when treated for
12 weeks; the difference in rates was not signiﬁcant (p = 0.2).
A subgroup analysis demonstrated SVR12 rates > 95% across
baseline factors traditionally associated with lower efﬁcacy.
G/P was well tolerated, with one DAA-related serious adverse
event (<0.1%); grade 3 laboratory abnormalities were rare.
Conclusions: G/P therapy for eight weeks in patients with
chronic HCV GT 1–6 infection without cirrhosis achieved an
overall SVR12 rate of 98% irrespective of baseline patient or viral
Keywords: Hepatitis C; Short duration; Direct-acting antiviral; Pangenotypic.
Received 31 October 2017; received in revised form 29 January 2018; accepted 5 March
2018; available online 16 March 2018
⇑ Corresponding author. Address: Department of Infectious Diseases, ASST Grande
Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.
Tel.: +39 0 26 44 42 189 – 2863; fax: +33 0 26 44 48 361.
E-mail address: massimo.puoti@fastwebnet.it (M. Puoti).Journal of Hepatology 2eek and 12-week
: An integrated analysis of HCV
s without cirrhosis
Wang3, David Mutimer4, Edward Gane5,
S. Lee8, Rui Marinho9, Jean-Francois Dufour10,
don13, Simone I. Strasser14, Paul J. Thuluvath15,
i Pilot-Matias3, Federico J. Mensa3
of London, Barts Health, London, UK; 3AbbVie Inc., North Chicago, IL,
it, Birmingham, UK; 5University of Auckland, Auckland, New Zealand;
; 7National Cheng Kung University Hospital, Tainan City, Taiwan;
ical School of Lisbon, University of Lisbon, Portugal; 10Hepatology,
spital, Switzerland; 11Université Paris Descartes and Hôpital Cochin,
M U955, Créteil, France; 13Henry Ford Health System, Detroit, MI, USA;
r and University of Maryland School of Medicine, Baltimore, MD, USA
characteristics; four additional weeks of treatment did not sig-
niﬁcantly increase the SVR12 rate, demonstrating that the opti-
mal treatment duration in this population is eight weeks.018 vol. 69 j 293–300
Research Article Viral Hepatitisinfection without cirrhosis: sofosbuvir plus ledipasvir, and
ombitasvir/paritaprevir/ritonavir plus dasabuvir. However, each
regimen has restrictions: treatment with sofosbuvir plus ledi-
pasvir for eight weeks is restricted by baseline HCV RNA level
(<6  106 IU/ml), prior HCV treatment experience (treatment
naïve), HIV-1 coinfection status (negative), and race (non-
black);9 patients treated with ombitasvir/paritaprevir/ritonavir
plus dasabuvir are eligible only for eight-week treatment in Eur-
ope, and treatment is restricted by viral subtype (genotype 1b),
prior HCV treatment experience (treatment naïve), and ﬁbrosis
stage (F0–F2).10 An eight-week, pangenotypic treatment option
for treatment-naïve patients without cirrhosis that provides
high response rates regardless of baseline patient or viral char-
acteristics could simplify treatment decisions and potentially
allow the treatment of more patients.
The DAAs glecaprevir (GLE; an inhibitor of the NS3/4A pro-
tease, identiﬁed by AbbVie and Enanta) and pibrentasvir (PIB;
an NS5A inhibitor) were coformulated for phase III studies to
comprise the once-daily, pangenotypic regimen GLE/PIB (G/P),
approved for the treatment of HCV genotype 1–6 infection.11,12
Both DAAs demonstrate a high barrier to resistance and potent
pangenotypic anti-HCV activity in vitro, with the half-maximal
effective concentration of GLE and PIB ranging from 0.85 to
4.6 nM and from 1.4 to 5.0 pM, respectively, across HCV geno-
types 1–6.13,14 GLE and PIB are minimally metabolized in the
liver, have negligible renal excretion, and exhibit a favourable
drug–drug interaction proﬁle with most commonly adminis-
tered concomitant medications.15 In phase II and III clinical
trials, treatment of patients without cirrhosis and with
compensated cirrhosis, including those with severe renal
impairment, with the all-oral, interferon-, and ribavirin-free
GLE and PIB combination regimen achieved rates of sustained
virologic response (SVR; HCV RNA level below the lower
limit of quantiﬁcation) at post-treatment week 12 (SVR12) of
93–100% across all six major HCV genotypes.16–19
Herein, data from nine trials were pooled to conduct an inte-
grated efﬁcacy analysis of 2,041 patients with HCV genotype 1–
6 infection without cirrhosis treated with the GLE and PIB com-
bination regimen for either 8 or 12 weeks, and to determine
whether any baseline factors impacted achievement of SVR12.
Patients and methods
Patients
Eligibility criteria are described herein for phase III studies; any
discrepancies in the criteria between phase II and III studies are
noted (Table S1). Adults aged 18 years or older with chronic
HCV genotype 1–6 infection (HCV RNA level >1,000 IU/ml) were
eligible for enrolment. Patients were either HCV treatment
naïve or HCV treatment experienced with interferon or pegy-
lated interferon with or without ribavirin, or sofosbuvir plus rib-
avirin with or without pegylated interferon. An eight-week
duration of G/P therapy was not evaluated in treatment-
experienced patients with HCV genotype 3 infection; therefore,
in this analysis comparing 8- and 12-week treatment durations,
all patients with HCV genotype 3 infection were treatment
naïve. In two studies (ENDURANCE-1 and EXPEDITION-2),
patients with HCV/HIV-1 coinfection were allowed to enroll.
Prior HCV treatment experience with a DAA other than sofosbu-
vir was exclusionary, as was coinfection with hepatitis B virus.
Active injection drug use was not exclusionary unless it could
preclude adherence to the protocol, per investigator assess-294 Journal of Hepatology 2ment. Absence of cirrhosis was documented by liver biopsy,
transient elastography, or serum biomarkers; cut-offs and inde-
terminate ranges (for FibroScan and FibroTest) are listed in
the supplementary material. All patients provided written
informed consent. Studies were designed according to good
clinical practice guidelines, the Declaration of Helsinki, and
applicable local regulations, with independent ethics committee
or institutional review board approval for all study sites.
Study design
Data were pooled from arms of nine phase II or III clinical trials
(EXPEDITION-2, -4, ENDURANCE-1, -2, -3, -4, SURVEYOR-I Part
2, SURVEYOR–II Parts 1 and 2, and SURVEYOR-II Part 4). Patients
received GLE at 300 mg and PIB at 120 mg (phase II formulation,
dosed as separate tablets) or coformulated G/P (300 mg/120 m
g; phase III formulation) without ribavirin orally dosed as three
pills once daily for either 8 or 12 weeks (Fig. 1). All authors had
access to the study data, and reviewed and approved the ﬁnal
manuscript for submission.
Assessments
HCV genotype and subtype were determined at screening with
use of the Versant HCV genotype Inno LiPA assay, version 2.0
(Siemens Healthcare Diagnostics, Tarrytown, NY, USA), and con-
ﬁrmed by phylogenetic analysis of viral sequences. Plasma HCV
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Fig. 1. Study design. The arms of the nine clinical trials from which patients
were pooled, including the number of patients enrolled by genotype (GT) in
either phase II or III studies. 1, SURVEYOR-I Part 2; 2, SURVEYOR-II Parts 1 and
2; 3, ENDURANCE-1; 4, ENDURANCE-2; 5, ENDURANCE-3; 6, SURVEYOR-II
Part 4; 7, ENDURANCE-4; 8, EXPEDITION-2; 9, EXPEDITION-4; GLE, glecapre-
vir; G/P, glecaprevir/pibrentasvir; PIB, pibrentasvir; TN, treatment naive.018 vol. 69 j 293–300
RNA was quantiﬁed by PCR; assay details are described in the
supplementary material. Next-generation sequencing was
conducted on samples from all patients at the baseline; the
presence of baseline polymorphisms at amino acid positions
in NS3 and NS5A relative to the HCV subtype-speciﬁc reference
sequence was evaluated with a 15% detection threshold in sam-
ples that had sequences available for both targets. The included
amino acid positions are those associated with resistance for
currently approved DAAs, and are listed in the supplementary
material and relevant table legend. Treatment-emergent amino
acid substitutions in NS3 and NS5A were analysed for patients
who experienced virologic failure. Treatment adherence was
determined by pill count. Safety was evaluated by monitoring
of adverse events, physical examinations, and laboratory test
assessments. Adverse events and their relatedness to the study
drugs were assessed by the study investigator.
Endpoints
The primary efﬁcacy endpoints were the number and percent-
age of patients who achieved SVR12; the analysis was con-
ducted in the intent-to-treat (ITT) population, which included
all patients who received at least one dose of the study drug.
The secondary efﬁcacy endpoints were the number and percent-
age of patients in the ITT population with on-treatment viro-
logic failure and post-treatment relapse.
Statistical analysis
Statistical tests and CIs were two-sided with a signiﬁcance level
of 0.05. CIs were determined by Wilson’s score method; overall
comparisons between treatment durations were evaluated by
Fisher’s exact test. Subgroup analyses were conducted in the
modiﬁed ITT (mITT) population, which excluded patients with
non-virologic failure (e.g. SVR12 non-response due to early dis-
continuation and/or lost to follow-up). A total of 19 variables
were included in the analysis to compare the SVR12 rates in
each subgroup following 8- vs. 12-week treatment. An addi-
tional subgroup analysis was performed on the treatment-
naïve and treatment-experienced patient cohorts. Lastly, the
potential interaction between treatment duration and 17 inde-
pendent variables (listed in Table S2) was examined separately
for each of those 17 variables in the mITT population with use of
a logistic regression model that includes the interaction effect
between treatment duration and the variable; Firth’s penalized
maximum likelihood estimation was used in all logistic regres-
sion analyses to handle quasi-complete separation due to sparse
SVR12 failures.
For further details regarding the methods used, please refer
to the CTAT table and supplementary information.
Results
This analysis included 2,041 patients infected with HCV geno-
type 1–6 without cirrhosis enrolled in phase II (N = 201) and
phase III (N = 1,840) studies between 8 September 2014 and
10 October 2016. For the remainder of the article, we refer to
the study drug as G/P, regardless of whether the phase II GLE
plus PIB regimen or the phase III coformulated G/P regimen
was administered. In total, 965 and 1,076 patients received
G/P for 8 and 12 weeks, respectively (Fig. 1). Baseline demo-
graphics and disease characteristics were generally similar
between the 8- and 12-week treatment groups (Table 1). Most
patients were white, male, and HCV treatment naïve. For the 8-
and 12-week treatment durations, 16% and 2%, respectively,were
coinfected with HIV-1, 11% had F3 ﬁbrosis, and 59% had plasma
HCV RNA >1  106 IU/ml at the baseline visit. Most patients
(80–83%) had no baseline drug class-speciﬁc amino acid poly-
morphisms in either NS3 or NS5A; polymorphisms in NS5A
(15–18%) were more common than those in NS3 (<1–1%), and
<1% of patients had baseline polymorphisms in both targets.
The SVR12 rate for patients with HCV genotype 1–6 infection
treated for eight weeks was 98% (943/965; 95% CI 96.6–98.5%),
and the SVR12 rate for patients treated for 12 weeks was 99%
(1,060/1,076; 95% CI 97.6–99.1%) (Fig. 2A). The difference in
SVR12 rates between the two treatment durations was not sig-
niﬁcant (p = 0.2). The rate of post-treatment relapse was 0.7%
(7/951; 95% CI 0.4–1.5%) and 0.3% (3/1,057; 95% CI 0.1–0.8%)
in patients treated for 8 and 12 weeks, respectively. The on-
treatment virologic failure rate was less than 1% regardless of
treatment duration: two of the 965 patients (0.2%) treated for
eight weeks and one of the 1,076 patients (<0.1%) treated for
12 weeks had on-treatment virologic failure (Table 2). Informa-
tion on patients with virologic failure, including baseline and
treatment-emergent resistance-associated substitutions, is
included (Table S3). Excluding patients with non-virologic fail-
ure, the mITT rate of SVR12 for the 8- and 12-week treatment
durations across all genotypes was 99.1% (943/952; 95% CI
98.2–99.5%) and 99.6% (1,060/1,064; 95% CI 99.0–99.9%) respec-
tively (Fig. 2B).
A subgroup analysis in the mITT population of 19 variables
showed that the SVR12 rates for patients treated for 8 vs. 12
weeks were similarly high (≥95%), regardless of variables such
as race, prior treatment experience, HCV/HIV-1 coinfection,
ﬁbrosis stage, viral load, proton pump inhibitor use, history of
injection drug use, and presence of baseline polymorphisms in
NS3 or NS5A (Fig. 3). The logistic regression analysis conﬁrmed
that SVR12 was not impacted by treatment duration, and that
there was no signiﬁcant difference in the rates of SVR12 in the
8- vs. 12-week arms for any of the baseline factors analysed,
including HCV genotype and presence of baseline
polymorphisms.
An additional subgroup analysis conducted in patients
receiving eight-week G/P therapy demonstrated high rates of
SVR12 (>95%; mITT) in HCV treatment-naïve patients across
subgroups traditionally associated with lower rates of response;
there were no virologic failures in patients older than 65 years,
with body mass index of ≥30 kg/m2, of black race, using con-
comitant PPIs, or with HIV-1 coinfection (Table S4). Importantly,
for all patient subgroups treated for eight weeks, there was no
clinically signiﬁcant difference in SVR12 rates between
treatment-naïve patients and those with HCV treatment
experience.
Safety was similar in patients treated for either 8 or 12
weeks with G/P (Table 3). The most common adverse events
were headache (17%) and fatigue (14%). Serious adverse events
occurred in 2% and 3% of patients treated for 8 and 12 weeks,
respectively. Adverse events leading to premature study drug
use discontinuation occurred in <1% of patients across both
treatment durations. Less than 1% of overall patients (and none
of those treated for eight weeks) had DAA-related serious
adverse events or discontinued use of the drug. Of the 2,041
total patients who received G/P, one (<0.1%) had a grade 3 ele-
vation in alanine aminotransferase level; the elevation was in
the context of cholelithiasis, and the patient achieved SVR12.
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Table 1. Baseline demographics and disease characteristics.
Characteristic 8-week G/P
Male, n (%) 5
Race, n (%)
White 7
Asian
Black
Age, median (range), years 52
BMI, median (range), kg/m2 25.5
Genotype, n (%)
1 4
Subtype 1a 2
Subtype 1b 2
Other
2 2
3 2
4
5
6
IL28B non-CC genotype, n (%) 6
HCV treatment naïve, n (%) 7
HCV treatment experienced, n (%)y 1
IFN-based 1
SOF-based
HCV RNA level, median (range), log10IU/ml 6.2
Baseline HCV RNA level, IU/ml, n (%)
<1  106 3
≥1  106 5
<6  106 7
≥6  106 2
Fibrosis stage, n (%)
F0–F1 7
F2
F3 1
Presence of baseline polymorphisms, n (%)d
NS3 only
NS5A only 1
Both NS3 and NS5A
None 7
HIV-1 coinfected, n (%) 1
Chronic kidney disease stage, n (%)||
Stage 4
Stage 5
Concomitant PPI use, n (%)
History of injection drug use, n (%)
Yes 4
Within the past 12 months–
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Receiving stable opiate substitution, n (%)
>80% treatment adherent, n (%)
APRI, n (%)
<1
≥1
FibroScan, n (%)**
<9.6 kPa (F2 cut-off)
≥9.6 kPa
FibroTest, n (%)**
<0.59
≥0.59
APRI, aspartate aminotransferase to platelet ratio; BMI, body mass index; G/P, gleca
interferon; PPI, proton pump inhibitor; ribavirin; SOF, sofosbuvir.
yIFN-based, IFN or pegylated IFN with or without ribavirin; SOF-based, SOF plus riba
N adjusted to exclude three patients with missing data.
dBaseline polymorphisms relative to subtype-speciﬁc reference sequence detected at
both targets at a drug class-speciﬁc subset of amino acid positions. NS3: 155, 156, 16
30, 92, 93 in genotype 2; 24, 28, 30, 31, 58, 93 in genotype 3; 24, 28, 30, 31, 93 in g
||Includes patients from the EXPEDITION-4 study only.
–Excludes patients from phase II studies and the phase III study SURVEYOR-2 Part 4
**N adjusted to exclude missing values; cut-offs per statistical analysis plan are desc296 Journal of Hepatology 2therapy (n = 965) 12-week G/P therapy (n = 1,076)
37 (56) 584 (54)
94 (82) 825 (77)
87 (9) 163 (15)
65 (7) 61 (6)
(19–84) 53 (20–83)
(17.3–65.7) 25.3 (17.4–54.1)
74 (49) 401 (37)
44 (25) 168 (16)
29 (24) 230 (21)
1 (0.1) 3 (0.3)
06 (21) 234 (22)
08 (22) 270 (25)
62 (6) 112 (10)
2 (0.2) 28 (3)
13 (1) 31 (3)
27 (65) 723 (67)
68 (80) 801 (74)
97 (20) 275 (26)
87 (19) 266 (97)
10 (1) 9 (3)
(0.7–7.6) 6.2 (2.5–7.8)
92 (41) 446 (41)
73 (59) 630 (59)
34 (76) 850 (79)
31 (24) 226 (21)
98 (83) 870 (81)
58 (6) 87 (8)
06 (11) 118 (11)
8 (<1) 14 (1)
41 (15) 184 (18)
3 (<1) 6 (<1)
65 (83) 809 (80)
52 (16) 18 (2)
n.a. 13 (1)
n.a. 70 (7)
72 (7) 125 (12)
27 (44) 371 (34)
23 (4) 15 (1)
53 (39) 316 (32)
73 (8) 63 (6)
48 (88) 979 (91)
93 (82) 881 (82)
72 (18) 195 (18)
96 (87) 703 (88)
92 (13) 98 (12)
22 (80) 292 (80)
81 (20) 75 (20)
evir/pibrentasvir; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; IFN,
irin plus pegylated IFN.
% next-generation sequencing threshold in samples that had sequences available for
NS5A: 28, 30, 31, 93, or H58D, E62A in genotype 1a; 31 or 93 in genotype 1b; 24, 28,
notype 4; 24, 28, 30, 31, 58, 92, 93 in genotypes 5 and 6.
data not collected).
bed in the supplementary material.018 vol. 69 j 293–300
Discussion
Treatment with all-oral, once daily G/P therapy for 8 or 12
weeks demonstrated high SVR12 rates (≥97%, mITT) across all
without cirrhosis with HCV genotype 1–6 infection; however,
that indication and duration are not approved in the USA, where
sofosbuvir/velpatasvir/voxilaprevir is indicated only as a 12-
week regimen for DAA-experienced patients.21,22 Treatment of
patients without cirrhosis with eight weeks of sofosbuvir/velpa
tasvir/voxilaprevir therapy resulted in an 8% relapse rate among
patients with the genotype 1a subtype compared with 0% in
those treated with 12 weeks of sofosbuvir/velpatasvir ther-
apy.23 In contrast, in patients without cirrhosis infected with
genotype 1a treated with G/P for eight weeks, the relapse rate
was 0%.
The extensive subgroup analysis conducted in patients
infected with genotype 1–6 without cirrhosis treated for 8 and
12 weeks with G/P conﬁrmed high rates of SVR12 regardless
of baseline characteristics traditionally associated with lower
efﬁcacy for other HCV regimens, such as treatment experience,
baseline NS3 or NS5A polymorphisms, race, HCV genotype/sub-
type, F3 ﬁbrosis, and high baseline viral load.17 Among patients
with F3 ﬁbrosis, the SVR12 rate (mITT) in patients treated for
eight weeks was 96.1% (99/103; 95% CI 90.4–98.5%) vs. 100%
(117/117; 95% CI 96.8–100%) in patients treated for 12 weeks;
the difference in SVR12 rates was not signiﬁcant. Of note, one
of the four F3 patients with virologic failure following eight
weeks of treatment had poor adherence and a low study drug
plasma concentration, which could account for the failure (an
on-treatment breakthrough). Among the nine patients (0.4%)
with baseline polymorphisms in both NS3 (position 155, 156,
or 168) and NS5A, there were two virologic failures, one for each
treatment duration; one of these failures was in a patient trea-
ted for eight weeks with low study drug exposures due to poor
adherence (mentioned earlier). Importantly, the lower SVR12
rates were in the context of small sample sizes consistent with
an NS5A and protease inhibitor-naïve population, and there is
no evidence indicating an efﬁcacy beneﬁt from using the
12-week over the eight-week duration in this population.
Finally, a logistic regression analysis conﬁrmed that there was
no statistically signiﬁcant difference in SVR12 rates across the
two treatment durations for any of the subgroups analysed.
G/P demonstrated a favourable safety and tolerability proﬁle
regardless of treatment duration in the 2,041 patients included
in this analysis. Regimens containing HCV protease inhibitors
have historically been associated with marked hyperbilirubine-
mia, elevated ALT, and gastrointestinal adverse events.24–26
However, in this integrated analysis, treatment with G/P
demonstrated a lower frequency of isolated grade 3 increases
in total bilirubin level (0.3%; 7/2,041) than other HCV protease
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Fig. 2. Integrated efficacy of glecaprevir/pibrentasvir (G/P). Rates of
sustained virologic response 12 weeks after treatment (SVR12) by genotype
and overall in patients treated for eight weeks (light blue) or 12 weeks (dark
blue) weeks in the (A) intent-to-treat (ITT) and (B) modiﬁed intent-to-treat
(mITT) populations. The modiﬁed intent-to-treat population excludes
patients with non-virologic failure). *Includes only genotype 3 patients who
were treatment naïve. HCV, hepatitis C virus.
Table 2. Reasons for non-response, pooled.
Reasons for non-response 8-week G/P
therapy (n = 965)
12-week G/P
therapy (n = 1,076)
Breakthrough, n (%) 2 (0.2)y 1 (<0.1)
Relapse, n (%) 7 (0.7)d 3 (0.3)||,–
Non-virologic failure
Discontinuation, n (%) 5 (0.5) 6 (0.6)
Missing SVR12 data, n (%) 8 (0.8) 6 (0.6)
*G/P, glecaprevir/pibrentasvir; SVR12, sustained virologic response 12 weeks after
treatment.
yOne genotype 1, one genotype 3.
One genotype 3.
dTwo genotype 2, ﬁve genotype 3.
||Three genotype 3.
–One patient with a history of injection drug use was later determined by
phylogenetic analysis to have a reinfection; no other reinfections were observed
in this analysis.
JOURNAL 
OF HEPATOLOGYsix major HCV genotypes, with <1% rate of relapse regardless
of treatment duration. There were no virologic failures in
patients with HCV genotype 4–6 infection, and treatment-
naïve patients with genotype 3 infection achieved SVR12 rates
of ≥95% regardless of 8- or 12-week treatment duration. These
high SVR rates were also achieved irrespective of key patient
or viral characteristics, and were consistent in patients with
HIV-1 coinfection (SVR12 rate of 99%) and severe renal impair-
ment (SVR12 rate of 98%20), with no virologic failures in either
subgroup.
For patients without cirrhosis, eight-week, pangenotypic
DAA regimens were not available until recently. G/P is now
approved in both the USA and Europe as an eight-week treat-
ment regimen for patients without cirrhosis across all geno-
types.11,12 In Europe, eight-week sofosbuvir/velpatasvir/
voxilaprevir therapy is approved for DAA-naïve patientsJournal of Hepatology 2inhibitors,23–25 and there were no incidences of drug-induced
liver injury. In addition, the frequency of diarrhoea following
treatment with G/P was 6% in this pooled analysis vs. 15–19%
for the sofosbuvir/velpatasvir/voxilaprevir regimen.23,27
Limitations of this integrated analysis include the low num-
ber of patients in some subgroups (speciﬁcally, the number of
patients with prior sofosbuvir experience, and those with geno-
type 5 or 6 infection), and the inclusion of patients from both
phase II and III clinical trials, which had marginally different
eligibility criteria.
Multiple DAA regimens are currently available for the
treatment of HCV infection; most of these are recommended
for 12 weeks of treatment.3,4,9,28–30 Two pangenotypic,
interferon- and ribavirin-free treatments are now available with
eight-week treatment durations.11,12,23 A pangenotypic regimen
that combines the high efﬁcacy expected from DAA-based018 vol. 69 j 293–300 297
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mtherapies with a treatment duration of eight weeks has the
potential advantages of reducing treatment burden and simpli-
fying treatment algorithms. Speciﬁcally, a pangenotypic option
without restrictions may eliminate the need for genotyping
and other baseline assessments (e.g. resistance-associated poly-
morphisms), which may not be available in resource-limited
settings. The minimal/no on-treatment monitoring provided
by a shorter treatment duration could increase treatment access
in areas with fewer specialized physicians (as complex treat-
ment algorithms typically require specialists). Taken together,
this suggests that the costs associated with medical visits and
diagnostic procedures will be reduced, and that the simplicity
of the regimen will make it more accessible to a greater number
of providers, potentially allowing the treatment of more
patients. Currently, most of the estimated 70 million individuals
with HCV infection are treatment naïve and do not have cirrho-
0 20 40 60 80 100
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lar carcinoma, and is the eighth leading cause of death in the
USA.31 Consequently, curative treatment of a larger number of
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own. APRI, aspartate aminotransferase to platelet ratio; BMI, body mass index;
an immunodeﬁciency virus; IDU, intravenous drug use; pegIFN, pegylatedtained virologic response has been associated with long-term
improvements in ﬁbrosis and other markers of liver
disease, as well as reductions in HCV-associated comorbidities
and extrahepatic manifestations.32sis, treatment with G/P achieved SVR12 rates of ≥98% with both
8 and 12 weeks of treatment, with similarly low rates of relapse
(<1%). Treatment for eight weeks achieved high SVR12 rates
regardless of HCV genotype/subtype, baseline viral load, ﬁbrosis
stage, NS3 or NS5A polymorphisms, or other baseline factors.
Excluding non-virologic failures, the SVR12 rate was 99.1% with018 vol. 69 j 293–300
studies and collected data. All authors participated in the inter-
pretation of the data, preparation, review, and approval of the
A
al
.
er
JOURNAL 
OF HEPATOLOGYeight-week G/P therapy. These results indicate that eight-week
G/P therapy is a highly efﬁcacious and well-tolerated pangeno-
typic therapy for most patients with chronic HCV infection.
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